On June 2nd, Dr. Michael Schweizer (Assistant Professor, Division of Medical Oncology University of Washington School of Medicine) spoke at our Active Surveillance Virtual Support Group with a presentation titled “Meds: A potential new path to keep men on AS?”
As a medical oncologist of the Fred Hutch Cancer Center in Seattle, he usually sees no patients on active surveillance for low- to favorable intermediate-risk prostate cancer. But this changed when he conducted a study of how apalutamide, a drug used in men with more advanced cancer, on men on AS.
Dr. Schweizer said: “My goal is to help reduce the morbidity and mortality associated with diseases like prostate cancer through developing novel drug therapies.” He plans to study the impact of other meds on men on AS to offer a new way of managing AS.
We want to thank Dr. Schweizer for answering questions!
Watch here:
To view the slides from this presentation, click here.
For information on our peer-led video chat ACTIVE SURVEILLANCE PROSTATE CANCER VIRTUAL SUPPORT GROUP, click here.
To SIGN UP for the Group or any other of our AnCan Virtual Support groups, visit our Contact Us page.